<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01191554</url>
  </required_header>
  <id_info>
    <org_study_id>FW2009006</org_study_id>
    <nct_id>NCT01191554</nct_id>
  </id_info>
  <brief_title>Dose-ranging Study of Tranexamic Acid in Valve Surgery</brief_title>
  <official_title>Comparison of Two Tranexamic Acid Dose Regimens on Postoperative Bleeding and Transfusion Needs in Primary Valve Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac surgical procedures account for a large amount of allogeneic transfusion. Tranexamic
      acid (TA), a synthetic antifibrinolytic drug, has been shown to reduce blood loss and
      transfusion requirements in cardiac surgery with Cardiopulmonary bypass. There are currently
      multiple dosing regimens for TA in cardiac surgery. Preliminary dose-response study has shown
      that low dose of TA would be as hemostatic efficacy as higher dose. Currently, no randomized
      study focus on TA in primary valve surgery. The aim of this prospective, double-blinded,
      randomized trial is to compare two dosing regimens of TA during primary valve surgery on
      perioperative blood loss and allogeneic blood transfusion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of allogeneic red blood cells transfused</measure>
    <time_frame>7 days post-operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chest tube drainage</measure>
    <time_frame>6 hours post-operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest tube drainage</measure>
    <time_frame>24 hours post-operation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">175</enrollment>
  <condition>Hemorrhage</condition>
  <condition>Valvular Heart Surgery</condition>
  <arm_group>
    <arm_group_label>High dosage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A loading dose of 30 mg/kg and a maintenance infusion of 16 mg/kg through out the operation, and 2 mg/kg into the cardiopulmonary bypass (CPB) prime volume.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dosage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A loading dose of 10 mg/kg and a maintenance infusion of 1 mg/kg through out the operation, and 1 mg/kg into the cardiopulmonary bypass (CPB) prime volume.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>High and low dosage. Loading dose followed by continuous infusion in operation.</description>
    <arm_group_label>High dosage</arm_group_label>
    <arm_group_label>Low dosage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  valvular disease patients requiring valvular replacement or repair surgery with
             cardiopulmonary bypass (CPB)

        Exclusion Criteria:

          -  a history of bleeding disorders

          -  active chronic hepatitis or cirrhosis

          -  chronic renal insufficiency (serum creatinine &gt; 2 mg/dl)

          -  preoperative anemia (Hb &lt; 10 g/dl)

          -  previous cardiac surgery

          -  urgent and emergency surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lihuan Li, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Fuwai Hospital &amp; Cardiovascular Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular Institute and Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2010</study_first_submitted>
  <study_first_submitted_qc>August 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2010</study_first_posted>
  <last_update_submitted>November 2, 2012</last_update_submitted>
  <last_update_submitted_qc>November 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Guyan Wang</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

